Pre-market top loser ZBH.SW Zimmer Biomet -4.26% on 27 Feb 2026: support CHF67.50
We see ZBH.SW stock slip in pre-market trading on 27 Feb 2026 after a CHF3.00 fall to CHF67.50, a -4.26% move from yesterday’s close on the SIX. Zimmer Biomet Holdings, Inc. (ZBH.SW) is the top loser in the Swiss session as traders react to weak near-term momentum and the gap from 50- and 200-day averages. We examine price drivers, valuation, technical risk and what Meyka AI’s model and grade suggest for short-term traders and longer-term investors.
Price action and trading drivers for ZBH.SW stock
ZBH.SW stock opened pre-market at CHF67.50 and recorded a one-day decline of -4.26%, with reported volume at 110.00 shares. The share sits at its intraday low and year low of CHF67.50, versus a year high of CHF119.00. This sharp pre-market move reflects limited liquidity and a high relative volume spike (relVol 36.67) that amplifies price moves in the SIX market.
Valuation snapshot and fundamentals for ZBH.SW stock
Zimmer Biomet shows an EPS of 2.77 and a trailing PE of 24.37 on the SIX, with market cap about CHF13,377,254,963.00. Key ratios: price/50-day CHF78.58, price/200-day CHF87.90, price-to-book 1.35, and free cash flow yield 9.14%. These metrics point to fair value relative to medical-device peers but limited upside unless margins improve or leverage falls.
Technicals, momentum and Meyka AI grades for ZBH.SW stock
Technicals show short-term stress: RSI 75.66 (overbought prior to the drop), ADX 84.17 (strong trend), and Keltner lower band near CHF67.90, close to the current price. Meyka AI rates ZBH.SW with a score out of 100: 77.55 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Earnings calendar, catalysts and ZBH.SW stock risks
Zimmer Biomet’s next earnings announcement is scheduled for 04 May 2026. Upcoming catalysts include procedure volumes in orthopaedics, margin updates and any debt-management moves. Primary risks: slowing net income growth (last fiscal net income fell -21.97% year), inventory days very high at 311.18, and net debt to EBITDA near 3.38, which leaves the stock sensitive to cyclical demand and rates.
Sector comparison and how ZBH.SW stock stacks up
In the Healthcare — Medical Devices peer group, average PE is about 35.33 and average ROE near 17.53%; Zimmer Biomet’s PE 24.37 and ROE 5.60% show valuation discount but weaker return metrics. The sector has YTD performance ~2.18%; ZBH.SW’s YTD is -4.26%, underperforming peers and increasing relative risk for momentum-driven portfolios.
Analyst outlook, price targets and ZBH.SW stock strategy
Analyst-style framing: near-term technical support sits at CHF67.50 and resistance at CHF78.58 (50-day). A conservative short-term price target is CHF55.00 (bear case), a base-case target CHF75.00 and upside case near prior trading levels CHF95.00. Traders can treat the current move as a short-term entry for a mean-reversion trade or a stop-loss trigger for longer-term holders while monitoring procedure volumes and the May earnings print. For more company details see Zimmer Biomet and our stock page at Meyka ZBH.SW.
Final Thoughts
ZBH.SW stock opened pre-market at CHF67.50 on 27 Feb 2026 after a -4.26% drop, trading at its year low. Fundamentals show a trailing PE of 24.37 and EPS 2.77, while free cash flow yield is 9.14% and net debt-to-EBITDA is 3.38, highlighting balance-sheet sensitivity. Meyka AI’s forecast model projects quarterly CHF63.20 (implied downside -6.37%) and yearly CHF57.27 (implied downside -15.16%) versus the current price of CHF67.50. Our view: the stock is exposed to near-term downside on weak procedure volumes and high inventory days, but a B+ Meyka grade indicates the company retains structural strengths in cash flow and product portfolio. Active traders should watch the May 2026 earnings date and the CHF67.50 support; longer-term investors should await clearer margin recovery or reduced leverage before adding materially. Forecasts are model-based projections and not guarantees.
FAQs
Why is ZBH.SW stock falling pre-market today?
ZBH.SW stock is down pre-market primarily from short-term selling, low liquidity and weak near-term momentum; the share hit CHF67.50 after a -4.26% move. Traders cite procedure-volume uncertainty and proximity to 50- and 200-day averages as catalysts for the decline.
What are the key fundamentals to watch for ZBH.SW stock?
Monitor EPS (2.77), PE (24.37), free cash flow yield (9.14%) and net debt-to-EBITDA (3.38). These drive valuation and liquidity risk for ZBH.SW stock and will shape market reaction at the next earnings release.
What does Meyka AI forecast for ZBH.SW stock this year?
Meyka AI’s forecast model projects a yearly target near CHF57.27, implying -15.16% from today’s CHF67.50. Forecasts are model-based projections and not guarantees; use them with other fundamental checks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.